Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies

References

• SolomonCGReducing cardiovascular risk in type 2 diabetesN Engl J Med2003348545745912556548
   PubMed Web of Science ®Google Scholar
• GaedePPedersenOTarget intervention against multiple-risk markers to reduce cardiovascular disease in patients with type 2 diabetesAnn Med200436535536615478310
   PubMed Web of Science ®Google Scholar
• GaedePVedelPLarsenNJensenGVHParvingHHPedersenOMultifactorial intervention and cardiovascular disease in patients with type 2 diabetesN Engl J Med2003348538339312556541
   PubMed Web of Science ®Google Scholar
• GaedePLund-AndersenHParvingHHPedersenOEffect of a multifactorial intervention on mortality in type 2 diabetesN Engl J Med2008358658059118256393
   PubMed Web of Science ®Google Scholar
• SkylerJSBergenstalRBonowROBuseJDeedwaniaPGaleEAMIntensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart AssociationDiabetes Care200932118719219092168
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) GroupLancet199835291318378539742976
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research GroupThe Effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitusN Engl J Med1993329149779868366922
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research GroupIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetesN Engl J Med2005353252643265316371630
   PubMed Web of Science ®Google Scholar
• The Action to Control Cardiovascular Risk in Diabetes Study GroupEffects of intensive glucose lowering in type 2 diabetesN Engl J Med2008358242545255918539917
   PubMed Web of Science ®Google Scholar
• The ADVANCE Collaborative GroupIntensive blood glucose control and vascular outcomes in patients with type 2 diabetesN Engl J Med2008358242560257218539916
   PubMed Web of Science ®Google Scholar
• DuckworthWAbrairaCMoritzTRedaDEmanueleNReavenPDGlucose control and vascular complications in veterans with type 2 diabetesN Engl J Med2009360212913919092145
   PubMed Web of Science ®Google Scholar
• HolmanRRPaulSKBethelMAMatthewsDRNeilHAW10-year follow-up of intensive glucose control in type 2 diabetesN Engl J Med2008359151577158918784090
   PubMed Web of Science ®Google Scholar
• CefaluWTGlycemic targets and cardiovascular diseaseN Engl J Med2008358242633263518539919
   PubMed Web of Science ®Google Scholar
• PatelAMacMahonSChalmersJNealBWoodwardMEffects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trialLancet2007370959082984017765963
   PubMed Web of Science ®Google Scholar
• KarallieddeJGnudiLACCORD and ADVANCE: a tale of two studies on the merits of glycaemic control in type 2 diabetic patientsNephrol Dial Transplant20082361796179818403430
   PubMed Web of Science ®Google Scholar
• ChalmersJCooperMEUKPDS and the legacy effectN Engl J Med2008359151618162018843126
   PubMed Web of Science ®Google Scholar
• 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertensionJ Hypertens20032161011105312777938
   PubMed Web of Science ®Google Scholar
• RuilopeLNew ADVANCEs in guidelinesJ Hypertens Suppl2008262S16S1818979719
   PubMedGoogle Scholar
• MogensenCNew treatment guidelines for a patient with diabetes and hypertensionJ Hypertens Suppl2003211S25S3012769164
   PubMedGoogle Scholar
• AbuissaHJonesPGMarsoSPO’KeefeJHJrAngiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: A meta-analysis of randomized clinical trialsJ Am Coll Cardiol200546582182616139131
   PubMed Web of Science ®Google Scholar
• The ONTARGET InvestigatorsTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med2008358151547155918378520
   PubMed Web of Science ®Google Scholar
• DavisBRFurbergCDWrightJTJrCutlerJAWheltonPthe ALLHAT Collaborative Research GroupALLHAT: Setting the record straightAnn Intern Med20041411394615238369
   PubMed Web of Science ®Google Scholar
• SalvettiAGhiadoniLThiazide diuretics in the treatment of hypertension: an updateJ Am Soc Nephrol2006174 Suppl 2S25S2916565243
   PubMed Web of Science ®Google Scholar
• D’AgostinoRBBelangerAJKannelWBCruickshankJMRelation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham StudyBMJ199130367993853891912805
   PubMed Web of Science ®Google Scholar
• StamlerJNeatonJDThe Multiple Risk Factor Intervention Trial (MRFIT) – importance then and nowJAMA2008300111343134518799447
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study GroupTight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38BMJ199831771607037139732337
   PubMed Web of Science ®Google Scholar
• RuilopeLHanssonLZanchettiAWhat have we learned from the HOT (hypertension optimal treatment) study?Nephrol Dial Transplant19971210204720489351060
   PubMed Web of Science ®Google Scholar
• HolmanRRPaulSKBethelMANeilHAWMatthewsDRLong-term follow-up after tight control of blood pressure in type 2 diabetesN Engl J Med2008359151565157618784091
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes – 2009Diabetes Care200932Suppl 1S13S6119118286
   PubMed Web of Science ®Google Scholar
• BuseJBGinsbergHNBakrisGLClarkNGCostaFEckelRPrimary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes AssociationDiabetes Care200730116217217192355
   PubMed Web of Science ®Google Scholar
• BolenSFeldmanLVassyJWilsonLYehH-CMarinopoulosSSystematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitusAnn Intern Med2007147638639917638715
   PubMed Web of Science ®Google Scholar
• KrentzAComparative safety of newer oral antidiabetic drugsExpert Opin Drug Saf20065682783417044809
   PubMed Web of Science ®Google Scholar
• KrumholzHMLeeTHRedefining quality – implications of recent clinical trialsN Engl J Med2008358242537253918539915
   PubMed Web of Science ®Google Scholar
• StrattonIMAdlerAINeilHAWMatthewsDRManleySECullCAAssociation of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ2000321725840541210938048
   PubMed Web of Science ®Google Scholar
• MilicevicZRazIStrojekKSkrhaJTanMWyattJHyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with Type 2 diabetes mellitus (HEART2D) Study designJ Diabetes Complications2005192808715745837
   PubMed Web of Science ®Google Scholar
• GersteinHYusufSRiddleMRydenLBoschJRationale, design, and baseline, Origin Trial Investigators, characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention)Am Heart J20081551263232.e1e618082485
   PubMed Web of Science ®Google Scholar
• MageeMIsleyWRationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) TrialAm J Cardiol20069712A20G30G
   PubMed Web of Science ®Google Scholar